To be conclusive, SENP2 suppresses HCC stemness and promotes its sensitivity to sorafenib through inactivating the AKT/GSK3β/CTNNB1 signaling pathway, indicating that SENP2 might be a potential treatment option for the management of HCC. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.